NewAmsterdam Pharma Company N.V. (NAMS)
Nasdaq · Healthcare · Biotechnology
$22.80−1.72%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.7B
- 52-week range
- $21.02 – $42.21
- 52-week change
- −27.97%
- EPS (trailing)
- −$2.16
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $22.5M (−50.61%)
- Net income
- −$203M
- Operating margin
- −1002.9%
- Diluted EPS
- −$1.72
- Free cash flow
- −$148M
From the company’s annual report on SEC EDGAR.
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Headquarters: Naarden, Netherlands · 100 employees · newamsterdampharma.com